Hepatitis C, Chronic: all 1,090 studies

Page 3 of 11. Open to participants first (9), then studies with results posted, then the rest; newest registration first within each.

• A Study to Evaluate the Safety and Effect of the Experimental Drugs ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 in Subjects With Chronic Hepatitis CCompletedNCT01674725Phase 3Results posted
• A Study to Evaluate ABT-450 With Ritonavir (ABT-450/r) and ABT-267 in Japanese Adults With Chronic Hepatitis C Virus InfectionCompletedNCT01672983Phase 2Results posted
• Durability of Virologic Response and/or Viral Resistance Patterns in Participants With Chronic Hepatitis C Who Have Been Previously Treated With Grazoprevir (MK-5172) (MK-5172-017)CompletedNCT01667081Results posted
• A Study of Predictors of the Effectiveness of Pegylated Interferon in a Cohort of Participants With Hepatitis CCompletedNCT01659567Results posted
• Dose Ranging of GSK2336805 in Combination TherapyCompletedNCT01648140Phase 2Results posted
• Sofosbuvir With Peginterferon Alfa 2a and Ribavirin for 12 Weeks in Treatment-Naive Subjects With Chronic Genotype 1, 4, 5, or 6 HCV InfectionCompletedNCT01641640Phase 3Results posted
• Japanese Phase II Study of SB-497115-GR in Hepatitis C Virus Infected PatientsCompletedNCT01636778Phase 2Results posted
• Study of Daclatasvir (BMS-790052) and Simeprevir (TMC435) in Patients With Genotype 1 Chronic Hepatitis C VirusCompletedNCT01628692Phase 2Results posted
• Open-Label Study of Sofusbuvir+Ribavirin With or Without Peginterferon Alfa-2a in Subjects With Chronic HCV Infection Who Participated in Prior Gilead HCV StudiesCompletedNCT01625338Phase 3Results posted
• A Study to Evaluate the Safety and Effect of Treatment With Experimental Antiviral Drugs in Combination With Peginterferon Alpha-2a and Ribavirin in People With Hepatitis C Virus Who Did Not Respond to Treatment in a Previous AbbVie/Abbott Combination StudyCompletedNCT01609933Phase 2Results posted
• Efficacy and Safety of Short Course Therapy With Peginterferon Alpha-2b (PEG-IFN Alfa-2b) and Ribavirin (RBV) for Chronic Hepatitis C (Genotype 4) Participants Achieving a Rapid Virological Response at Week 4 of Treatment (MK-8908B-059)TerminatedNCT01606800Phase 4Results posted
• Sofosbuvir + Ribavirin for 12 or 16 Weeks in Treatment Experienced Subjects With Chronic Genotype 2 or 3 HCV Infection (FUSION)CompletedNCT01604850Phase 3Results posted
• An Observational Study of Dual and Triple Therapies Based on Pegasys (Peginterferon Alfa-2a) in Patients With Chronic Hepatitis CCompletedNCT01604291Results posted
• A Triple Combination Therapy Study of Boceprevir, Pegasys and Copegus in Previously Untreated Patients With Genotype 1 Chronic Hepatitis CCompletedNCT01591460Phase 4Results posted
• A Study of The Relationship Between Drop in Hemoglobin and Sustained Virological Response in Patients With Chronic Hepatitis C Treated With Copegus (Ribavirin) and Pegasys (Peginterferon Alfa-2a)CompletedNCT01585324Phase 4Results posted
• Herpes Simplex Type 1 Suppression in Hepatitis CCompletedNCT01580995Phase 2Results posted
• Intra-Individual Reproducibility of the Non-Invasive Assessment of the Portal CirculationCompletedNCT01579162Not applicableResults posted
• Drug-drug Interaction of BI 201335 and MicrogynonCompletedNCT01570244Phase 1Results posted
• Study to Assess the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of ABT-267 in HCV Infected SubjectsCompletedNCT01563536Phase 2Results posted
• Safety and Efficacy of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Interleukin-28B CC Allele-Positive Chronic Hepatitis C Virus (HCV) Genotype 1 Participants (P07755)CompletedNCT01544920Phase 3Results posted
• Drug Utilization of Boceprevir and Clinical Management of Health Outcomes of Interest in Chronic Hepatitis C Participants (P08518)CompletedNCT01544582Results posted
• Sofosbuvir + Ribavirin for 12 Weeks in Subjects With Chronic Genotype 2 or 3 Hepatitis C Infection Who Are Interferon Intolerant, Interferon Ineligible or Unwilling to Take InterferonCompletedNCT01542788Phase 3Results posted
• This Trial Evaluates Safety, Pharmacokinetic Profile and Anti-viral Response of BI 207127 and BI 201335 for Patients With Chronic Hepatitis CCompletedNCT01528735Phase 2Results posted
• Drug Drug Interaction Study Between BI 201335 and BI 207127 in Chronic Hepatitis C Infected PatientsCompletedNCT01525628Phase 1Results posted
• An Observational Study of Peginterferon (e.g. Pegasys)-Based Direct Acting Antiviral Triple Therapy in Patients With Chronic Hepatitis C Genotype 1CompletedNCT01508130Results posted
• Alisporivir With PEG and RBV in Protease Inhibitor (PI) Treatment Failure Patients With Chronic Hepatitis CTerminatedNCT01500772Phase 3Results posted
• Open-Label, Bridging Study of Telaprevir in Treatment-Naïve and Treatment-Experienced Russian Patients With Genotype 1 Chronic Hepatitis CCompletedNCT01498068Phase 3Results posted
• Study Comparing Daclatasvir (BMS-790052) With Telaprevir Combined With Peginterferon Alfa-2a and Ribavirin in Patients With Chronic Hepatitis C Virus InfectionCompletedNCT01492426Phase 3Results posted
• A Study to Assess the Safety, Tolerability and Efficacy of TMC435 Along With Pegylated Interferon Alpha-2a (Pegasys) and Ribavirin (Copegus) Triple Therapy in Chronic Hepatitis C Genotype-1 Infected Patients Co-infected With Human Immunodeficiency Virus-Type 1CompletedNCT01479868Phase 3Results posted
• Efficacy and Safety of MP-424, Peginterferon Alfa-2b and Ribavirin in Non-responder Genotype 2 Hepatitis C Infected PatientsCompletedNCT01468584Phase 3Results posted
• Telaprevir, Peg-IFN-alfa-2a, and RBV in Treatment-Experienced Black/African American and Non-Black/African American Subjects With Genotype 1 Chronic Hepatitis CTerminatedNCT01467492Phase 4Results posted
• A Study of TMC435 in Combination With PSI-7977 (GS7977) in Chronic Hepatitis C Genotype 1-Infected Prior Null Responders To Peginterferon/Ribavirin Therapy or HCV Treatment-Naive PatientsCompletedNCT01466790Phase 2Results posted
• Efficacy and Safety of MP-424, Peginterferon Alfa-2b and Ribavirin in Relapser Genotype 2 Hepatitis C Infected PatientsCompletedNCT01466192Phase 3Results posted
• ABT-450 With Ritonavir and ABT-267 and/or ABT-333 With and Without Ribavirin in Genotype 1 Hepatitis C Virus Infected PatientsCompletedNCT01464827Phase 2Results posted
• Efficacy of a 12-Week Regimen of Telaprevir, Pegylated Interferon, and Ribavirin in Treatment-Naive and Prior Relapser Subjects With Interleukin28B (IL28B) CC GenotypeTerminatedNCT01459913Phase 3Results posted
• A Study to Evaluate Paritaprevir With Ritonavir (ABT-450/r) When Given Together With Ombitasvir and With and Without Ribavirin (RBV) in Treatment-Naïve Participants With Genotype 1, 2 or 3 Chronic Hepatitis C Virus (HCV)CompletedNCT01458535Phase 2Results posted
• Evaluating Three Grams Daily Valacyclovir in Patients With Chronic Hepatitis C and HSV-2 Infection (Phase I)CompletedNCT01453075Phase 1Results posted
• An Observational Study on Dual And Triple Therapies Based on Peginterferon Alfa (e.g. Pegasys) in Patients With Chronic Hepatitis CCompletedNCT01447446Results posted
• A Study of Sustained Virological Response in Relation to IL28-b Expression in Treatment-Naïve Patients With Chronic Hepatitis C Genotype 1 on Combination Treatment With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin)CompletedNCT01447420Phase 4Results posted
• Alisporivir (Deb025) and Boceprevir Triple Therapies in African American Participants Not Previously Treated for Chronic Hepatitis C Genotype 1TerminatedNCT01446250Phase 3Results posted
• Grazoprevir (MK-5172) With Peg-Interferon and Ribavirin in Participants With Chronic Genotype 2 or 3 Hepatitis C (MK-5172-012)TerminatedNCT01440595Phase 2Results posted
• Safety, Antiviral Activity, and Pharmacokinetics of GSK2336805 With Peginterferon and Ribavirin in Chronic Hepatitis C SubjectsCompletedNCT01439373Phase 2Results posted
• A Study Evaluating Slow Response/Non-Rapid Response in Patients With Chronic Hepatitis C, Genotype 1, 2, 3 & 4 Treated With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin)CompletedNCT01429792Phase 4Results posted
• The Effect of Boceprevir in Russian Participants Diagnosed With Chronic Hepatitis C Genotype 1 (P08160)CompletedNCT01425203Phase 3Results posted
• Pharmacokinetics of Boceprevir in Pediatric Subjects With Chronic Hepatitis C Genotype 1 (P07614)TerminatedNCT01425190Phase 1Results posted
• An Observational Study of Pegasys (Peginterferon Alfa-2a) Plus Copegus (Ribavirin) in Participants With Chronic Hepatitis C (CHC), Genotype 2, 3, 1 or 4, Undergoing Opioid Maintenance TherapyCompletedNCT01416610Results posted
• The Effect of High Dose Vitamin C on the Liver Function in Chronic Hepatitis PatientsCompletedNCT01413360Phase 4Results posted
• Study of Vaniprevir Plus PegIntron®/Ribavirin in Japanese Participants With Chronic Hepatitis C Who Relapsed After Treatment (MK-7009-044)CompletedNCT01405937Phase 3Results posted
• Vaniprevir Plus PegIntron®/Ribavirin in Japanese Participants With Chronic Hepatitis C Who Are Non-responders to Previous Treatment (MK-7009-045)CompletedNCT01405560Phase 3Results posted
• Impact of Physician Directed Education on Patient Compliance With Hepatitis C TherapyCompletedNCT01405027Phase 4Results posted
• Phase III Trial of BI 201335 (Faldaprevir) in Treatment Naive (TN) and Relapser Hepatitis C Virus (HCV)-Human Immunodeficiency Virus (HIV) Coinfected Patients (STARTverso 4)CompletedNCT01399619Phase 3Results posted
• An Observational Study on Predictive Factors of Response in Patients With Chronic Hepatitis C Treated With Pegasys (Peginterferon Alfa-2a) and RibavirinCompletedNCT01392742Results posted
• Safety and Efficacy of Boceprevir in Asia Pacific Participants With Chronic Hepatitis C Genotype 1 (P07063)CompletedNCT01390844Phase 3Results posted
• 100% VS 80% Of Pegasys In Koreans With Chronic Hepatitis C (CHC)CompletedNCT01378104Phase 4Results posted
• Vaniprevir Administered With Pegylated-interferon and Ribavirin in Japanese Treatment-Naïve Chronic Hepatitis C Participants (MK-7009-043)CompletedNCT01370642Phase 3Results posted
• A Study of TMC435 in Participants With Genotype 1 Hepatitis C Virus (HCV) InfectionCompletedNCT01366638Phase 3Results posted
• A Collaborative Trial in Injectors of Individualized Treatment for Genotype 2/3CompletedNCT01364090Phase 4Results posted
• Study to Determine the Safety and Effectiveness of Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) in Patients Who Have Previously Not Received the Standard of CareCompletedNCT01359644Phase 2Results posted
• Efficacy and Safety of BI 201335 (Faldaprevir) in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-Experienced Genotype 1 Hepatitis C Infected Patients (STARTverso 3)CompletedNCT01358864Phase 3Results posted
• Chronic Hepatitis C Virus Related Thrombocytopenia to Evaluate the Effects of E5501CompletedNCT01355289Phase 2Results posted
• Grazoprevir (MK-5172) Administered With Peginterferon and Ribavirin in Treatment-Naïve Participants With Chronic Hepatitis C (MK-5172-003)CompletedNCT01353911Phase 2Results posted
• Evaluating Safety and Efficacy In Hepatitis C Patients After PegIntron Pen Treatment (Study P04896)TerminatedNCT01340573Results posted
• The Study of Gut Associated Lymphocytes in HIV and HCV/HIV Co-infected PatientsCompletedNCT01335230Results posted
• Sofosbuvir With Pegylated Interferon and Ribavirin Hepatitis C Virus (HCV) Genotypes 1,4,5,6CompletedNCT01329978Phase 2Results posted
• Study of ABT-267 in Treatment Naive Hepatitis C Virus (HCV) Genotype 1 Infected SubjectsCompletedNCT01314261Phase 2Results posted
• A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of ABT-450 With Ritonavir (ABT-450/r) When Given Together With ABT-333 and Ribavirin (RBV) in Treatment-Naïve and Non-responder Subjects With Genotype 1 Chronic Hepatitis C Virus (HCV) InfectionCompletedNCT01306617Phase 2Results posted
• A Phase III Study of TMC435 in Treatment-naive, Genotype 1, Hepatitis C-infected PatientsCompletedNCT01292239Phase 3Results posted
• A Study of TMC435 in Genotype 1, Hepatitis C-infected Patients Who Relapsed After Previous Interferon (IFN)-Based TherapyCompletedNCT01290731Phase 3Results posted
• A Phase III Study of TMC435 in Genotype 1, Hepatitis C-infected Participants Who Failed to Respond to Previous IFN-based TherapyCompletedNCT01288209Phase 3Results posted
• A Retrospective Study to Assess the Impact of the Use of Interferon in Patients With Chronic Hepatitis C (DECISION)CompletedNCT01280656Results posted
• Efficacy of Nitazoxanide in the Treatment of Chronic Hepatitis C Virus (HCV)CompletedNCT01276756Phase 2/3Results posted
• Open-Labeled Study of PSI-7977 and RBV With and Without PEG-IFN in Treatment-Naïve Patients With HCV GT2 or GT3CompletedNCT01260350Phase 2Results posted
• A Study of PEGASYS (Peginterferon Alfa-2a) Plus Ribavirin in Patients With Chronic Hepatitis C (CHC), Genotype 2 or 3CompletedNCT01258101Phase 4Results posted
• VX-950-C211 - A Dosing Regimen Study (Twice Daily Versus Every 8 Hours) of Telaprevir in Treatment-naïve Participants With Genotype 1 Chronic Hepatitis C Virus InfectionCompletedNCT01241760Phase 3Results posted
• Safety And Efficacy Of Oral PF-4136309 In Patients With Chronic Hepatitis C Infection And Abnormal Liver EnzymesTerminatedNCT01226797Phase 2Results posted
• An Observational Study on Long-Term Persistence of Resistant Mutations And Durability of Sustained Virological Response in Patients With Chronic Hepatitis C Treated With Direct Acting Antiviral (DAA)- Containing RegimensTerminatedNCT01168856Results posted
• Hepatic Safety of Raltegravir Versus Efavirenz as HIV Therapy for Patients With HIV and HCV CoinfectionCompletedNCT01147107Phase 4Results posted
• Safety, Antiviral Effect and PK of BI 207127 + BI 201335 +/- RBV for 4 up to 40 Weeks in Patients With Chronic HCV Genotype 1 InfectionCompletedNCT01132313Phase 2Results posted
• Post Marketing Observational Study of Retreatment of Chronic Hepatitis C With Peginterferon Alpha and Ribavirin (Study P06011)CompletedNCT01098097Results posted
• Concentration-Controlled Ribavirin for the Treatment of Patients With Chronic Hepatitis C Virus InfectionCompletedNCT01097395Phase 4Results posted
• A Study of Administration of Peginterferon Alfa-2a [Pegasys] by Autoinjector Versus Pre-filled Syringe in Patients With Chronic Hepatitis CCompletedNCT01087944Phase 1Results posted
• A Randomized Study to Evaluate the Safety, Tolerability and Antiviral Activity of ABT-450, ABT-333 and ABT-072CompletedNCT01074008Phase 2Results posted
• PROPHESYS 1: An Observational Study on Predictors of Response in Treatment-naïve Patients With Chronic Hepatitis C Virus (HCV)Treated With Pegasys (Peginterferon Alfa-2a)CompletedNCT01070550Results posted
• PROPHESYS 3: Observational Study on Predictors of Response in Patients With Treatment-naïve Chronic Hepatitis C Initiated on Treatment With Pegasys (Peginterferon Alfa-2a) or Peginterferon-alfa-2bCompletedNCT01066819Results posted
• PROPHESYS 2: An Observational Study on Predictors of Response in Treatment-naïve Patients With Chronic Hepatitis C Treated With Pegasys (Peginterferon Alfa-2a) or Peginterferon-alfa-2bCompletedNCT01066793Results posted
• Observational Study of Patients With Chronic Hepatitis C Virus (HCV) Infected With HCV Genotype 1 Low Virus Load (LVL 1) and Effect of PegIntron Plus Rebetol Treatment (Study P04793 Part 2)CompletedNCT01054742Results posted
• VX-950-TiDP24-C219: A Roll Over Trial for Patients in the Control Group of the C216 Study Who Received Telaprevir PlaceboCompletedNCT01054573Phase 3Results posted
• A Study of Extended Therapy of PEGASYS (Peginterferon Alfa-2a) in Combination With COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C and Slow ResponseCompletedNCT01033448Phase 4Results posted
• Boceprevir/Peginterferon/Ribavirin for Chronic Hepatitis C: Erythropoietin Use Versus Ribavirin Dose Reduction for Anemia (P06086 AM2)CompletedNCT01023035Phase 3Results posted
• A Study to Assess the Effectiveness, Safety, and Pharmacokinetics of TMC435 in Combination With Peginterferon Alfa-2a and Ribavirin in Hepatitis-C Infected PatientsCompletedNCT00996476Phase 2Results posted
• Study to Assess the Effect of BMS-790052 on the Pharmacokinetics of Ortho Tri-Cyclen® in Healthy Female SubjectsCompletedNCT00983957Phase 1Results posted
• Pharmacokinetics of Vaniprevir (MK-7009) and Hepatitis C Virus RNA Levels After Vaniprevir Treatment (MK-7009-029)TerminatedNCT00954993Phase 1Results posted
• A Study of Vaniprevir (MK-7009) in Participants With Chronic Hepatitis C Infection After Participation in Other Vaniprevir Studies (MK-7009-028)CompletedNCT00943761Phase 2Results posted
• A Study of Ribavirin in Combination With PEGASYS (Peginterferon Alfa-2a (40KD))in Patients With Chronic Hepatitis CCompletedNCT00922779Phase 4Results posted
• Boceprevir Treatment in Participants With Chronic Hepatitis C Genotype 1 Deemed Nonresponders to Peginterferon/Ribavirin (P05514)CompletedNCT00910624Phase 3Results posted
• 4 Week Combination of BI 207127 NA With Peg-IFN and Ribavirin in Chronic HCV PatientsCompletedNCT00905632Phase 1Results posted
• A Study of Safety and Efficacy of Vaniprevir Administered With Pegylated-Interferon and Ribavirin in Japanese Participants With Chronic Hepatitis C Infection (7009-016)CompletedNCT00880763Phase 2Results posted
• Quality of Life During Treatment of Chronic Hepatitis C (P05278/MK-4031-336)CompletedNCT00863109Results posted
• MRKAd5 HIV-1 Gag Vaccine (V520) in Subjects With Chronic Hepatitis C (V520-022) (COMPLETED)CompletedNCT00857311Phase 1Results posted
• ATHENAS - Retrospective Study of Compliance in Chronic Hepatitis C With Pegylated Interferon Alfa-2b/Ribavirin in Brazil (P05632)TerminatedNCT00856024Results posted

← Hepatitis C, Chronic overview